Development of human-like scFv-Fc neutralizing botulinum neurotoxin E

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Miethe, Sebastian ^a   Rasetti Escargueil, Christine ^b   Avril, Arnaud ^c   Liu, Yvonne ^b   Chahboun, Siham ^c   Korkeala, Hannu ^d   Mazuet, Christelle ^e   Popoff, Michel Robert ^e   Pelat, Thibaut ^c,f   Thullier, Philippe ^c   Sesardic, Dorothea ^b   Hust, Michael ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^d UNIVERSITY OF HELSINKI   (Finland)

^e INSTITUT PASTEUR   (France)

^f BIOTEM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN E; PROTEINASE; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE FC FRAGMENT NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; BOTULINUM TOXIN; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOTULISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; EX VIVO STUDY; HEMIDIAPHRAGM; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOPHARMACOLOGY; IN VITRO STUDY; IN VIVO STUDY; LD50; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; PHAGE DISPLAY; PHRENIC NERVE PARALYSIS; PROTECTION; ANIMAL; CLOSTRIDIUM BOTULINUM; EPITOPE MAPPING; HUMAN; IMMUNOLOGY; MACACA;

ANIMALS; ANTIBODIES, NEUTRALIZING; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; EPITOPE MAPPING; HUMANS; MACACA; MICE; SINGLE-CHAIN ANTIBODIES;

EID: 84947969581     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139905     Document Type: Article

References (64)

1. Sobel J. Botulism. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005; 41: 1167-1173. doi: 10.1086/444507
2. Fujinaga Y, Sugawara Y, Matsumura T. Uptake of botulinum neurotoxin in the intestine. Curr Top Microbiol Immunol. 2013; 364: 45-59. doi: 10.1007/978-3-642-33570-9-3 PMID: 23239348
3. Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013; 306: 124-146. doi: 10.1016/j.tox.2013.02.006 PMID: 23435179
4. Weber JT, Hibbs RG, Darwish A, Mishu B, Corwin AL, Rakha M, et al. A massive outbreak of type E botulism associated with traditional salted fish in Cairo. J Infect Dis. 1993; 167: 451-454. PMID: 8421179
5. Hibbs RG, Weber JT, Corwin A, Allos BM, Abd el Rehim MS, Sharkawy SE, et al. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis Off Publ Infect Dis Soc Am. 1996; 23: 337-340.
6. Jalava K, Selby K, Pihlajasaari A, Kolho E, Dahlsten E, Forss N, et al. Two cases of food-borne botulism in Finland caused by conserved olives, October 2011. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2011; 16: 20034.
7. Pingeon JM, Vanbockstael C, Popoff MR, King LA, Deschamps B, Pradel G, et al. Two outbreaks of botulism associated with consumption of green olive paste, France, September 2011. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2011; 16: 20035.
8. Raphael BH, Shirey TB, Lúquez C, Maslanka SE. Distinguishing highly-related outbreak-associated Clostridium botulinum type A(B) strains. BMC Microbiol. 2014; 14: 192. doi: 10.1186/1471-2180-14-192 PMID: 25031122
9. Gupta A, Sumner CJ, Castor M, Maslanka S, Sobel J. Adult botulism type F in the United States, 1981-2002. Neurology. 2005; 65: 1694-1700. doi: 10.1212/01.wnl.0000187127.92446.4c PMID: 16344510
10. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001; 285: 1059-1070. PMID: 11209178
11. Froude JW, Stiles B, Pelat T, Thullier P. Antibodies for biodefense. mAbs. 2011; 3: 517-527. doi: 10.4161/mabs.3.6.17621 PMID: 22123065
12. Bozheyeva G, Kunakbayev Y, Yeleukenov D. Former Soviet Biological Weapons Facilities in Kazakhstan: Past, Present, and Future. Montrerey Inst Int Stud. 1999;Occasional Paper No. 1.
13. Broad WJ. SOWING DEATH: A special report.; How Japan Germ Terror Alerted World. The New York Times. 26 May 1998. Available: http://www.nytimes.com/1998/05/26/world/sowing-death-a-specialreport-how-japan-germ-terror-alerted-world.html. Accessed 22 Sep 2014.
14. Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A. 2005; 102: 9984-9989. doi: 10.1073/pnas.0408526102 PMID: 15985558
15. Horowitz BZ. Type E botulism. Clin Toxicol Phila Pa. 2010; 48: 880-895. doi: 10.3109/15563650.2010.526943
16. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982; 46: 86-94. PMID: 6806598
17. Mazuet C, Sautereau J, Legeay C, Bouchier C, Bouvet P, Popoff MR. An atypical outbreak of foodborne botulism due to Clostridium botulinum types B and E from ham. J Clin Microbiol. 2015; 53: 722-726. doi: 10.1128/JCM.02942-14 PMID: 25428161
18. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000; 80: 717-766. PMID: 10747206
19. Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, et al. Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem. 2008; 283: 3997-4003. doi: 10.1074/jbc.M707917200 PMID: 18032388
20. Kukreja RV, Sharma SK, Singh BR. Molecular basis of activation of endopeptidase activity of botulinum neurotoxin type E. Biochemistry (Mosc). 2010; 49: 2510-2519. doi: 10.1021/bi902096r
21. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004; 44: 167-193. doi: 10.1146/annurev.pharmtox.44.101802.121554 PMID: 14744243
22. Tonello F, Morante S, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulism neurotoxins: a novel group of zinc-endopeptidases. Adv Exp Med Biol. 1996; 389: 251-260. PMID: 8861019
23. Dressler D. Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. J Neurol. 2013; 260: 701-713. doi: 10.1007/s00415-012-6615-2 PMID: 22878428
24. Lim ECH, Seet RCS. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol. 2010; 6: 624-636. doi: 10.1038/nrneurol.2010.149 PMID: 21045798
25. Centers for Disease Control and Prevention (CDC). Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep. 2010; 59: 299. PMID: 20300057
26. Long SS. Infant botulism and treatment with BIG-IV (BabyBIG). Pediatr Infect Dis J. 2007; 26: 261-262. PMID: 17484226
27. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006; 354: 462-471. doi: 10.1056/NEJMoa051926 PMID: 16452558
28. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980; 69: 567-570. PMID: 7191633
29. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005; 73: 5450-5457. doi: 10.1128/IAI.73.9.5450-5457.2005 PMID: 16113261
30. Thullier P, Chahboun S, Pelat T. A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. mAbs. 2010; 2: 528-538. PMID: 20562531
31. Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, et al. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PloS One. 2009; 4: e6625. doi: 10.1371/journal.pone.0006625 PMID: 19675673
32. Hülseweh B, Rülker T, Pelat T, Langermann C, Frenzel A, Schirrmann T, et al. Human-like antibodies neutralizing Western equine encephalitis virus. mAbs. 2014; 6: 718-727. doi: 10.4161/mabs.28170 PMID: 24518197
33. Rülker T, Voß L, Thullier P, O' Brien LM, Pelat T, Perkins SD, et al. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PloS One. 2012; 7: e37242. doi: 10.1371/journal.pone.0037242 PMID: 22666347
34. Chassagne S, Laffly E, Drouet E, Hérodin F, Lefranc M-P, Thullier P. A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol Immunol. 2004; 41: 539-546. doi: 10.1016/j.molimm.2004.03.040 PMID: 15183932
35. Pelat T, Hust M, Hale M, Lefranc M-P, Dübel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol. 2009; 9: 60. doi: 10.1186/1472-6750-9-60 PMID: 19563687
36. Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc M-P, et al. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother. 2005; 49: 3414-3420. doi: 10.1128/AAC.49.8.3414-3420.2005 PMID: 16048955
37. Pelat T, Hust M, Laffly E, Condemine F, Bottex C, Vidal D, et al. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother. 2007; 51: 2758-2764. doi: 10.1128/AAC.01528-06 PMID: 17517846
38. Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, et al. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. mAbs. 2014; 6: 446-459. doi: 10.4161/mabs.27773 PMID: 24492304
39. Kubota T, Watanabe T, Yokosawa N, Tsuzuki K, Indoh T, Moriishi K, et al. Epitope regions in the heavy chain of Clostridium botulinum type E neurotoxin recognized by monoclonal antibodies. Appl Environ Microbiol. 1997; 63: 1214-1218. PMID: 9097417
40. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel PEDS. 2011; 24: 321-331. doi: 10.1093/protein/gzq111 PMID: 21149386
41. Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, et al. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem. 2012; 430: 141-150. doi: 10.1016/j.ab.2012.08.005 PMID: 22922799
42. USDA. Animal Welfare Act and Animal Welfare Regulations. U.S. Government Printing Office; 2013.
43. National Research Council. Guide for the Care and Use of Laboratory Animals. Eight Edition. Washington, D.C.: The National Academies Press; 2011.
44. Pelat T, Hust M, Thullier P. Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem. 2009; 9: 1633-1638. PMID: 20105119
45. Kügler J, Wilke S, Meier D, Tomszak F, Frenzel A, Schirrmann T, et al. Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC Biotechnol. 2015; 15: 10. doi: 10.1186/s12896-015-0125-0 PMID: 25888378
46. Carter P, Bedouelle H, Winter G. Improved oligonucleotide site-directed mutagenesis using M13 vectors. Nucleic Acids Res. 1985; 13: 4431-4443. PMID: 2989795
47. Jäger V, Büssow K, Wagner A, Weber S, Hust M, Frenzel A, et al. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol. 2013; 13: 52. doi: 10.1186/1472-6750-13-52 PMID: 23802841
48. Schuck P, Minton AP. Analysis of mass transport-limited binding kinetics in evanescent wave biosensors. Anal Biochem. 1996; 240: 262-272. doi: 10.1006/abio.1996.0356 PMID: 8811920
49. Jones RGA, Ochiai M, Liu Y, Ekong T, Sesardic D. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J Immunol Methods. 2008; 329: 92-101. doi: 10.1016/j.jim.2007.09.014 PMID: 17976638
50. Chahboun S, Hust M, Liu Y, Pelat T, Miethe S, Helmsing S, et al. Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol. 2011; 11: 113. doi: 10.1186/1472-6750-11-113 PMID: 22111995
51. Rasetti-Escargueil C, Jones RGA, Liu Y, Sesardic D. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon Off J Int Soc Toxinology. 2009; 53: 503-511. doi: 10.1016/j.toxicon.2009.01.019
52. Rasetti-Escargueil C, Liu Y, Rigsby P, Jones RGA, Sesardic D. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon Off J Int Soc Toxinology. 2011; 57: 1008-1016. doi: 10.1016/j.toxicon.2011.04.003
53. Froude JW, Thullier P, Pelat T. Antibodies against anthrax: mechanisms of action and clinical applications. Toxins. 2011; 3: 1433-1452. doi: 10.3390/toxins3111433 PMID: 22174979
54. Bakherad H, Mousavi Gargari SL, Rasooli I, Rajabibazl M, Mohammadi M, Ebrahimizadeh W, et al. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH). Mol Biotechnol. 2013; 55: 159-167. doi: 10.1007/s12033-013-9669-1 PMID: 23666874
55. Thullier P, Huish O, Pelat T, Martin ACR. The humanness of macaque antibody sequences. J Mol Biol. 2010; 396: 1439-1450. doi: 10.1016/j.jmb.2009.12.041 PMID: 20043919
56. Thullier P, Avril A, Mathieu J, Behrens CK, Pellequer J-L, Pelat T. Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor. PloS One. 2013; 8: e65855. doi: 10.1371/journal.pone.0065855 PMID: 23741517
57. Avril A, Froude JW, Mathieu J, Pelat T, Thullier P. Isolation of antibodies from non-human primates for clinical use. Curr Drug Discov Technol. 2014; 11: 20-27. PMID: 23410051
58. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods San Diego Calif. 2005; 36: 3-10. doi: 10.1016/j.ymeth.2005.01.001
59. Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol Baltim Md 1950. 2002; 169: 1119-1125.
60. Hust M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, et al. A human scFv antibody generation pipeline for proteome research. J Biotechnol. 2011; 152: 159-170. doi: 10.1016/j.jbiotec.2010.09.945 PMID: 20883731
61. Rosenwasser LJ, Busse WW, Lizambri RG, Olejnik TA, Totoritis MC. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol. 2003; 112: 563-570. PMID: 13679816
62. Pathan NI, Zou A, Chu P, Wynne D, Leigh B, Hanna N. Lumiliximab (IDEC-152), an anti-CD23 antibody, induces apoptosis in vitro and in vivo in CLL cells. AACR Meet Abstr. 2004; 2004: 163.
63. Pelat T, Thullier P. Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies. mAbs. 2009; 1: 377-381. PMID: 20068407
64. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc M-P, Thullier P. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol. 2008; 384: 1400-1407. doi: 10.1016/j.jmb.2008.10.033 PMID: 18976662